HARBIN GLORIA PHARMACEUTIC

Harbin Gloria Pharmaceuticals (HGP) thrives amid a bullish Chinese market, offering stable injectable and oral drugs with strong distribution, yet faces modest growth and potential volatility as institutional interest remains low.

China’s A‑share market rises on 13 Aug, driven by pharma innovation. Harbin Gloria, a steady mid‑cap, stands to gain from the sector’s bullish trend and strong R&D pipeline.